0001179110-21-000315.txt : 20210106 0001179110-21-000315.hdr.sgml : 20210106 20210106160627 ACCESSION NUMBER: 0001179110-21-000315 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210104 FILED AS OF DATE: 20210106 DATE AS OF CHANGE: 20210106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Almstead Neil Gregory CENTRAL INDEX KEY: 0001578850 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 21510524 MAIL ADDRESS: STREET 1: C/O PTC THERAPEUTICS, INC. STREET 2: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 4 1 edgar.xml FORM 4 - X0306 4 2021-01-04 0 0001070081 PTC THERAPEUTICS, INC. PTCT 0001578850 Almstead Neil Gregory C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 0 1 0 0 Chief Technical Ops Officer Common Stock 2021-01-04 4 M 0 7229 27.05 A 34318 D Common Stock 2021-01-04 4 S 0 7229 60.591 D 27089 D Common Stock 2021-01-04 4 M 0 32771 27.05 A 59860 D Common Stock 2021-01-04 4 S 0 32571 60.576 D 27289 D Common Stock 2021-01-04 4 S 0 200 61.245 D 27089 D Common Stock 2021-01-04 4 M 0 3035 11.23 A 30124 D Common Stock 2021-01-04 4 S 0 2935 60.559 D 27189 D Common Stock 2021-01-04 4 S 0 100 61.36 D 27089 D Common Stock 2021-01-04 4 M 0 2188 11.23 A 29277 D Common Stock 2021-01-04 4 S 0 2188 60.542 D 27089 D Common Stock 2021-01-04 4 M 0 4188 18.01 A 31277 D Common Stock 2021-01-04 4 S 0 4188 60.588 D 27089 D Common Stock 2021-01-04 4 M 0 5715 11.23 A 32804 D Common Stock 2021-01-04 4 S 0 5615 60.56 D 27189 D Common Stock 2021-01-04 4 S 0 100 61.24 D 27089 D Common Stock 2021-01-04 4 M 0 187 18.01 A 27276 D Common Stock 2021-01-04 4 S 0 187 60.608 D 27089 D Common Stock 2021-01-04 4 M 0 48125 18.01 A 75214 D Common Stock 2021-01-04 4 S 0 47936 60.575 D 27278 D Common Stock 2021-01-04 4 S 0 189 61.24 D 27089 D Common Stock 2021-01-04 4 M 0 600 10.85 A 2512 I By Spouse Common Stock 2021-01-04 4 S 0 600 60.65 D 1912 I By Spouse Stock Option (Right To Buy) 27.05 2021-01-04 4 M 0 7229 27.05 D 2024-01-27 Common Stock 7229 32771 D Stock Option (Right to Buy) 27.05 2021-01-04 4 M 0 32771 27.05 D 2024-01-27 Common Stock 32771 0 D Stock Option (Right to Buy) 11.23 2021-01-04 4 M 0 3035 11.23 D 2027-01-02 Common Stock 3035 7903 D Stock Option (Right to Buy) 11.23 2021-01-04 4 M 0 2188 11.23 D 2027-01-02 Common Stock 2188 5715 D Stock Option (Right To Buy) 18.01 2021-01-04 4 M 0 4188 18.01 D 2028-01-02 Common Stock 4188 65812 D Stock Option (Right to Buy) 11.23 2021-01-04 4 M 0 5715 11.23 D 2027-01-02 Common Stock 5715 0 D Stock Option (Right to Buy) 18.01 2021-01-04 4 M 0 187 18.01 D 2028-01-02 Common Stock 187 65625 D Stock Option (Right to Buy) 18.01 2021-01-04 4 M 0 48125 18.01 D 2028-01-02 Common Stock 48125 17500 D Stock Option (Right to Buy) 10.85 2021-01-04 4 M 0 600 10.85 D 2023-05-15 Common Stock 600 0 I By Spouse Stock Option (Right To Buy) 490.8 2021-04-27 Common Stock 216.0 216 D Stock Option (Right To Buy) 218.4 2022-01-10 Common Stock 166.0 166 D Stock Option (Right To Buy) 51.0 2025-01-01 Common Stock 69550.0 69550 D Stock Option (Right To Buy) 30.86 2026-01-03 Common Stock 55000.0 55000 D Stock Option (Right To Buy) 33.02 2029-01-21 Common Stock 72500.0 72500 D Stock Option (Right To Buy) 33.02 2029-01-21 Common Stock 17500.0 17500 D Stock Option (Right To Buy) 51.16 2030-01-28 Common Stock 69500.0 69500 D Stock Option (Right to Buy) 490.8 2021-04-27 Common Stock 7 7 I By Spouse Stock Option (Right to Buy) 218.4 2022-01-10 Common Stock 7 7 I By Spouse Stock Option (Right to Buy) 27.05 2024-01-27 Common Stock 1300 1300 I By Spouse Stock Option (Right to Buy) 51 2025-01-01 Common Stock 2060 2060 I By Spouse The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on November 24, 2020. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.40 to $61.25 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.18 to $61.12 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $61.24 to $61.25 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on November 10, 2020. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.22 to $60.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.42 to $60.75 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.39 to $61.24 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.20 to $61.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.40 to $61.24 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.18 to $61.12 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the spouse of the Reporting Person on November 10, 2020. Currently exercisable. This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023. This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021. /s/ Avraham S. Adler, attorney-in-fact 2021-01-06